Skip to main content

Envoy Medical, Inc.

corporate_fare Company Profile

Envoy Medical, Inc.

COCH·NASDAQ·Industrial Applications And Services·CIK 0001840877

Envoy Medical, Inc. is a hearing health company that develops innovative medical technologies for various types of hearing loss. The company aims to provide hearing devices that leverage the ear's natural anatomy, specifically by using an implanted sensor to capture sound energy from the ossicular chain (the three small hearing bones connecting the eardrum to the cochlea). This sensor converts mechanical energy into a signal that can be processed and amplified to meet a patient's specific hearing needs. Envoy Medical's initial product, the Esteem FI-AMEI, received FDA approval in 2010. It is the only FDA-approved fully implanted active hearing implant available. Despite its unique status, the Esteem FI-AMEI faced commercial challenges, primarily because the Centers for Medicaid and Medicare Services (CMS) classified it as a hearing aid, which limited coverage eligibility. The company continues to seek proper classification for the Esteem FI-AMEI as a Fully Implanted Active Middle Ear Implant. Globally, approximately 1,000 Esteem FI-AMEI devices have been implanted, including some during clinical trials in the early 2000s. This has provided Envoy Medical with over two decades of experience with its implantable sensor technology, which has demonstrated itself as a viable alternative to external or implanted microphones.

Envoy Medical, Inc. (NASDAQ:COCH) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors COCH SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Envoy Medical Finalizes Highly Dilutive $30M Offering at Deep Discount Amidst Going Concern Warning
  • Envoy Medical Registers Additional $13.4M in Securities, Expanding Highly Dilutive Offering
  • Envoy Medical Files Highly Dilutive S-1 Offering Amidst Going Concern Warning and Nasdaq Delisting Threats

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$241K
Net Income
-$23.76M
Diluted EPS
-$1.23
Op. Cash Flow
-$18.2M
Free Cash Flow
-$18.38M
Gross Profit
-$633K
Operating Income
-$22.27M
Cash & Equivalents
$3.74M
Debt / Equity
0.00×
Net Margin
-98.57×
Shares Outstanding
23.26M sh
Source: 10-K · filed 2026-04-13 · accession 0001213900-26-043011
$0.6418 +0.01% today
52-week range · as of 2026-05-22 $0.3625 – $1.89
Market cap
$48.27M
Volume
57.3K (0.5× avg)
3-mo avg 126.8K
Live data · 2026-06-14 06:17 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed COCH - Filings & News (Page 2)

COCH
Feb 12, 2026, 8:42 AM EST
Filing Type: 424B4
Importance Score:
10
Price at Filing: $0.5866
Real-time Price: $0.6418 info
Change: +$0.0552 (+9%) info
Market Cap: $48.274M info
COCH
Feb 11, 2026, 9:13 AM EST
Filing Type: S-1MEF
Importance Score:
9
Price at Filing: $0.420
Real-time Price: $0.6418 info
Change: +$0.2218 (+53%) info
Market Cap: $48.274M info
COCH
Feb 06, 2026, 10:58 AM EST
Filing Type: S-1/A
Importance Score:
9
Price at Filing: $0.5499
Real-time Price: $0.6418 info
Change: +$0.0919 (+17%) info
Market Cap: $48.274M info